Funder: National Institutes of Health
Due Dates: June 20, 2025 (New/Renewal/Resubmission/Revision) | February 20, 2026 (New/Renewal/Resubmission/Revision) | June 22, 2026 (New/Renewal/Resubmission/Revision)
Funding Amounts: No budget limit; UG3 phase: 1–2 years, UH3 phase: 3–4 years, max 5 years total; actual budget must reflect project needs.
Summary: Supports development and validation of digital health technology-derived biomarkers and outcome assessments for remote monitoring as clinical trial endpoints across at least three diseases, requiring collaboration with patient advocacy organizations.
Key Information: Applicants must include at least three diseases/conditions and partner with non-profit patient advocacy groups; contact NIH if requesting ≥$500,000 direct costs/year.